Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:ATAI NASDAQ:EPRX NASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$13.58$15.16$4.64▼$18.60$1.51B-0.111.23 million shs374,095 shsATAIAtai Beckley$4.28-0.9%$3.96$2.00▼$6.75$1.58B1.595.12 million shs3.31 million shsEPRXEupraxia Pharmaceuticals$7.34+3.4%$7.16$3.82▼$9.32$443.56M1.19217,069 shs258,637 shsPGENPrecigen$4.15-2.1%$3.95$1.28▼$5.47$1.48B1.074.19 million shs3.78 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals0.00%+5.60%-20.31%-7.68%+155.74%ATAIAtai Beckley0.00%+4.10%-6.70%-1.14%+109.71%EPRXEupraxia Pharmaceuticals0.00%+6.13%-0.84%-12.24%+83.46%PGENPrecigen0.00%+4.18%+2.66%+6.53%+209.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$13.58$15.16$4.64▼$18.60$1.51B-0.111.23 million shs374,095 shsATAIAtai Beckley$4.28-0.9%$3.96$2.00▼$6.75$1.58B1.595.12 million shs3.31 million shsEPRXEupraxia Pharmaceuticals$7.34+3.4%$7.16$3.82▼$9.32$443.56M1.19217,069 shs258,637 shsPGENPrecigen$4.15-2.1%$3.95$1.28▼$5.47$1.48B1.074.19 million shs3.78 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals0.00%+5.60%-20.31%-7.68%+155.74%ATAIAtai Beckley0.00%+4.10%-6.70%-1.14%+109.71%EPRXEupraxia Pharmaceuticals0.00%+6.13%-0.84%-12.24%+83.46%PGENPrecigen0.00%+4.18%+2.66%+6.53%+209.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.77Moderate Buy$23.0069.37% UpsideATAIAtai Beckley 2.91Moderate Buy$16.00273.83% UpsideEPRXEupraxia Pharmaceuticals 2.89Moderate Buy$18.33149.77% UpsidePGENPrecigen 2.33Hold$11.00165.06% UpsideCurrent Analyst Ratings BreakdownLatest EPRX, PGEN, AMLX, and ATAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026EPRXEupraxia Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.005/14/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.005/14/2026PGENPrecigen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/14/2026PGENPrecigen Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$9.00 ➝ $11.005/8/2026AMLXAmylyx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/7/2026EPRXEupraxia Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/4/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/28/2026AMLXAmylyx Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$19.00 ➝ $21.004/22/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/21/2026EPRXEupraxia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PGENPrecigen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M17.28N/AN/A$2.46 per share5.52ATAIAtai Beckley$4.09M385.27N/AN/A$0.69 per share6.20EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$1.76 per shareN/APGENPrecigen$9.68M152.84N/AN/A$0.06 per share69.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)ATAIAtai Beckley-$660.05M-$2.23N/AN/AN/A-19,019.44%-89.79%-63.58%8/13/2026 (Estimated)EPRXEupraxia Pharmaceuticals-$38.58M-$1.05N/AN/AN/AN/A-87.56%-51.20%8/11/2026 (Estimated)PGENPrecigen-$250.64M-$1.18N/A12.21N/A-646.99%717.50%58.48%8/11/2026 (Estimated)Latest EPRX, PGEN, AMLX, and ATAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026PGENPrecigen-$0.03-$0.02+$0.01-$0.02$20.81 million$23.25 million5/12/2026Q4 2025ATAIAtai Beckley-$0.11-$0.08+$0.03-$0.08$0.22 million$0.95 million5/12/2026Q1 2026EPRXEupraxia Pharmaceuticals-$0.22-$0.23-$0.01-$0.23N/AN/A5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A3/25/2026Q4 2025PGENPrecigen-$0.10-$0.01+$0.09-$0.01$8.29 million$4.57 million3/19/2026Q4 2025EPRXEupraxia Pharmaceuticals-$0.16-$0.37-$0.21-$0.37N/AN/A3/7/2026Q4 2025ATAIAtai Beckley-$0.12-$0.05+$0.07-$1.73$1.50 million$1.07 million3/3/2026Q4 2025AMLXAmylyx Pharmaceuticals-$0.31-$0.30+$0.01-$0.30($0.05) millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/AATAIAtai BeckleyN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A17.8517.85ATAIAtai Beckley0.027.907.90EPRXEupraxia Pharmaceuticals0.0219.3119.31PGENPrecigen4.624.824.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%ATAIAtai Beckley28.41%EPRXEupraxia PharmaceuticalsN/APGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals12.30%ATAIAtai Beckley26.80%EPRXEupraxia PharmaceuticalsN/APGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals200111.19 million97.51 millionOptionableATAIAtai Beckley80368.17 million269.50 millionOptionableEPRXEupraxia Pharmaceuticals2960.43 millionN/AN/APGENPrecigen190356.51 million188.59 millionOptionableEPRX, PGEN, AMLX, and ATAI HeadlinesRecent News About These CompaniesPrecigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare ConferenceMay 26 at 8:05 AM | prnewswire.comPrecigen (NASDAQ:PGEN) Stock Rating Upgraded by Wall Street ZenMay 23 at 1:19 AM | americanbankingnews.comPrecigen (PGEN): The Best Penny Stock to Buy for Long TermMay 22, 2026 | insidermonkey.comPrecigen: Why I Am More Cautious After The Q1 Beat (Downgrade)May 21, 2026 | seekingalpha.comPrecigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of "Hold" by BrokeragesMay 21, 2026 | americanbankingnews.comEquities Analysts Set Expectations for Precigen Q3 EarningsMay 18, 2026 | marketbeat.comEarnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 16, 2026 | finance.yahoo.comPrecigen (NASDAQ:PGEN) Given New $11.00 Price Target at Citizens JmpMay 15, 2026 | americanbankingnews.comPrecigen (NASDAQ:PGEN) Stock, Earnings Estimates, EPS, And RevenueMay 14, 2026 | benzinga.comPrecigen Earnings Call Highlights PAPZIMEOS Launch SurgeMay 14, 2026 | tipranks.comPrecigen IncMay 14, 2026 | edition.cnn.comPrecigen Inc (PGEN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...May 14, 2026 | finance.yahoo.comPrecigen’s lead cancer therapy is fueling a massive stock rally — here’s what Wall Street sees nextMay 14, 2026 | msn.comPrecigen jumps after Q1 beat as Papzimeos launch momentum takes holdMay 14, 2026 | msn.comPrecigen: Full Commercial Validation And Room To RunMay 14, 2026 | seekingalpha.comWhy is Precigen stock surging today?May 14, 2026 | za.investing.comPrecigen anticipates funding through cash flow breakeven by end of 2026 as PAPZIMEOS launch scalesMay 14, 2026 | seekingalpha.comPrecigen (PGEN) Q1 2026 Earnings TranscriptMay 14, 2026 | fool.comPrecigen Q1 Earnings Call HighlightsMay 13, 2026 | marketbeat.comPrecigen, Inc. (PGEN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comPrecigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Amylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026EPRX, PGEN, AMLX, and ATAI Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$13.58 0.00 (0.00%) As of 03:03 PM EasternAmylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Atai Beckley NASDAQ:ATAI$4.28 -0.04 (-0.93%) As of 03:04 PM EasternAtai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Eupraxia Pharmaceuticals NASDAQ:EPRX$7.34 +0.24 (+3.38%) As of 03:03 PM EasternEupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Precigen NASDAQ:PGEN$4.15 -0.09 (-2.12%) As of 03:03 PM EasternPrecigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
